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E-mail address: michael.schreiber@bni.uni-hambuThe N-glycan g15 within the HIV-1 gp120 V3 loop efﬁciently blocks antibodies to facilitate viral
escape from humoral immune responses. However, we have isolated primary viruses all lacking
the N-glycosylation site g15 due to mutations (NNNT > YRNA, HNTV, SIQK), which showed resistance
to neutralizing antibodies present in autologous or heterologous HIV-1 positive sera. When intro-
duced into the NL4-3 background, the sequences YRNA, HNTV and SIQK caused an increase of viral
infectivity and resistance to neutralization. Thus, despite the lack of g15, primary isolates can escape
from neutralization because of speciﬁc mutations of the NNNT sequence altering coreceptor usage.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The external human immunodeﬁciency virus type-1 (HIV-1)
envelope glycoprotein gp120 is a highly glycosylated protein with
more than 60% of its molecular mass being carbohydrate structures
[1]. These complex carbohydrates, especially within the gp120 V3
loop, are able to block binding of neutralizing antibodies [2–4] to
allow escape from humoral immune responses [5]. An efﬁcient vir-
al entry into target cells requires the interaction of the gp120 with
(i) heparansulfateproteoglycan [6], (ii) the CD4 receptor [7] and
(iii) at least one of the two coreceptors CXCR4 or CCR5 [8]. A region
of gp120 that binds to the coreceptors is the hypervariable V3 loop
[9,10]. Within the V3 loop sequences of subtype B viruses, a con-
served sequence motif N81N98N96T97 [11] is present, which con-
tains the N-glycosylation site g15 (counting for NL4-3). By
sequence data analysis it was revealed that NNT is present in
96% of all B subtype V3 loop sequences listed [11]. Mutations with-
in the NNT motif can destroy the original g15 N-glycosylation site
but the additional N amino acid of the NNNT motif can rescue the
N-glycosylation site [12]. All these data demonstrate that the g15
N-glycosylation site within the V3 loop is highly conserved. This
further suggests that in vivo a strong selective pressure for the
presence of the g15 N-glycan might exist.chemical Societies. Published by E
rg.de (M. Schreiber).An important function of N-glycan g15 is the shielding of the V3
loop [13], leading to the highly efﬁcient blockade of neutralizing
antibody [2–5,14–16]. Another role of g15 is its supportive role
for the infection of cells when CCR5 is used as a coreceptor [17].
R5-tropic viruses showed higher infection rates when g15 was
present and infection was impaired by mutations destroying the
NNT g15 site [4]. For CXCR4-speciﬁc infection the function of N-
glycan g15 is completely the opposite [4,13]. X4-tropic viruses
lacking g15 because of a single amino acid exchange N301Q,
showed higher infection rates but these viruses become highly
sensitive to neutralization [13,18,19]. From all these experiments
it was concluded that N-glycan g15 is blocking neutralizing anti-
body and viruses lacking g15 become highly sensitive to neutral-
ization by V3-loop speciﬁc antibodies.
In general, the exchange NNT > QNT is a well-accepted method
to transform a functional N-glycosylation site into a non-functional
site to study the role of complex carbohydrates in HIV-1 infection
[4,13,20,21], but the QNT sequence is not detectable in patient de-
rived HIV-1 primary isolates. In our study, we now have identiﬁed
primary viruses lacking the N-glycosylation site for N-glycan g15.
These primary viruses showed an atypically mutated g15 region
where 3–4 of 4 amino acids were replaced (NNNT amino acids,
300–303, Fig 1A). However, such atypical mutations have also been
identiﬁed in other primary isolates [22] or are present in V3 se-
quences published by the HIV sequence database [11]. As men-
tioned before, mutations within the V3 loop affect the usage of
coreceptors, antibody binding and N-glycosylation. Since the V3lsevier B.V. All rights reserved.
Fig. 1. V3 loop sequences of primary isolates and construction of NL4-3 mutants. (A) V3 loop sequences were aligned to the B clade consensus sequence. Boxed, mutated N-
glycosylation sites. PI, primary isolates. NL, these NL4-3 mutants are differing in amino acids position 300–303. (B) Construction of pNL mutants. Proviral DNA from primary
isolate infected cells was PCR ampliﬁed and cloned into bacterial plasmid pCRTM. A single characterized bacterial clone was used for mutagenesis by overlap extension PCR to
generate the V3 loops only differing in the NNNT amino acid sequnece. The V3 PCR fragment was cloned into pUCenv-DV3 and characterized by DNA sequencing. From the
pUCenv plasmid the env gene was cloned as a BstEII-BamHI fragment into the pNL4-3-Bst vector to generate a functional provirus.
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V3 loop amino acid sequence will have a signiﬁcant impact on
coreceptor usage and the efﬁciency of viral entry. The efﬁciency
of viral entry can be estimated as the speciﬁc infectivity of a virus
mutant to allow comparison between different viruses.
Here, we have investigated the role of mutated NNNT motifs
(YRNA, SIQK, HNTV) from V3 loops of primary isolates for viral
infectivity and neutralization in the context of primary viruses
and in the context of mutated NL4-3 viruses. Our data suggest that
the lack of protection, provided by the N-glycan g15 against neu-
tralizing antibodies, can be compensated by speciﬁc amino acid
mutations in the NNNT region, which enhanced the speciﬁc infec-
tivity of the respective virus mutant.2. Materials and methods
2.1. HIV-1 primary isolates
The six primary isolates were obtained from serum samples of
ﬁve AIDS patients. All AIDS patients were anti-HIV-1 seropositive
as conﬁrmed by standard Western immunoblot and enzyme
immunoassay and were classiﬁed as stages III–IV c–d according
to the Centers for Disease Control (CDC) classiﬁcation. To isolate
the primary virus, PBMC-free serum samples were applied to phy-
tohemagglutinin (PHA) and interleukin-2 (IL-2) activated HIV-1
negative donor PBMC as described before [22]. Brieﬂy, donor PBMC
Table 1
Speciﬁc infectivity of primary isolates.
HIV-1
primary
isolates
V3 loop
overall
positive
charge
K + R  DE
(incl. His)
Presence of
N-glycosylation
site g15
Syncytia
inducing
phenotypea
Speciﬁc
infectivityb
TCID/ngp24
PI-903 +3 (+5) Yes NSI 140
PI-991 +3 (+4) Yes NSI 650
PI-951 +4 (+6) Yes NSI 1.600
PI-932 +5 (+9) No SI 7.600
PI-911 +8 (+8) No SI 9.400
PI-930 +7 (+10) No SI 14.900
a Syncytia phenotype was analyzed using MT2 cells as well as PBMC.
b Speciﬁc infectivity was analyzed in PHA/IL-2 stimulated PBMC.
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serum. Infection of donor PBMC was monitored by a V3-speciﬁc
PCR followed by a p24 assay. The cell culture supernatants (1000
TCID) were added to 1  105 MT-2 cells and syncytia formation
was monitored on day 5. The growth of primary isolates in cell cul-
tures was monitored by sequence analysis of the V3 loop region.
From infected donor PBMC proviral DNA was isolated and PCR
ampliﬁed [22]. The PCR fragment was cloned into the pCRTM plas-
mid and transformed into E. coli. For each PCR ampliﬁcation 20 sin-
gle recombinant bacterial clones were sequenced (Beckmann
Coulter, CEQ 2000 XL) to monitor the sequence homogeneity of
the V3 loop region. The sequence analysis revealed that for each
of the primary isolates the 20 clones had identical sequences. This
20-clone-sequencing-procedure was also used to control the neu-
tralization experiments. In all the experiments sequence analysis
revealed that no genetic variation could be detected in the ana-
lyzed V3 loop region before and after the neutralization
experiments.
2.2. Neutralization assay
Interleukin-2 and PHA stimulated PBMC (2  106 cells/ml) were
infected with PBMC cell culture supernatants containing 1000 TCID
of the respective primary isolate. To study neutralization, 50 ll of
virus supernatant was mixed with 50 ll of the respective serum
sample and incubated for 1 h at 37 C prior to infection. For infec-
tion 100 ll of cell culture medium containing 2  106 PBMC/ml
was given to the virus/serum mixture. HIV-1 patient serum was
tested at a concentration of 5% and p24 antigen was monitored
at day 5. Genetic variation during viral growth was not observed
by the 20-clone-sequence-procedure as described above (Section
2.2).
2.3. NL4-3 mutants
Cloning of NL4-3 mutants was carried out as described earlier
[4,13]. In brief, the V3 region of the NL4-3 virus was replaced by
a BglII and NheI DNA fragment generated by overlap extension
PCR from a single bacterial clone containing the V3 loop of the
respective primary isolate. The resulting env gene was cloned as
a BstEII–BamHI fragment into NL4-3-Bst to obtain the complete
viral vector (see Fig 1B). Vector DNA was transfected into HeLa
cells and viral production was measured by an in-house p24 assay.
2.4. p24-Assay
For p24 detection in PBMC cultures an in-house assay was used
[23]. In brief, ELISA plates (Nunc, maxisorb 96-well) were coated
with 100 ll/well Protein-G afﬁnity puriﬁed monoclonal antibody
11-G-7 (10 lg/ml) before incubation with cell-culture supernatant.
After washing with PBS containing 0.1% Tween 20 the plates were
incubated with a horseradish peroxidase conjugated antibody 10-
E-7 at 2.5 lg/ml. After 30 min, the plates were washed and bound
10-E-7 antibody was detected using orthophenylene diamine as
peroxidase substrate, and the reaction was stopped after 10 min
by 1 M H2SO4. The sensitivity of the assay was >1 ng p24/ml.
2.5. Coreceptor assay
Infection of GHOST coreceptor indicator cell lines was moni-
tored by p24 immunostaining as described earlier [24]. All GHOST
cell lines express human CD4 and in addition one of the possible
coreceptors for HIV-1, i.e. CCR3, CCR5, CCR8, CXCR4, CXCR6,
CX3CR1, or GPR15. In brief, infected GHOST cells were grown in
Dulbeccos modiﬁed medium containing 10% fetal calf serum for
5 days, washed in phosphate-buffered-saline (PBS) and ﬁxed usingmethanol–acetone (20 C, 1:1). A mixture of two mouse mono-
clonal anti-p24 antibodies (EVA365, EVA366) was used at a
1:400 dilution. Bound antibody was detected by a goat anti-mouse
IgG antibody conjugated to -galactosidase (1:100 dilution, Biomol,
Germany). Staining was performed using 0.5 mg 5-bromo-4-
chloro-3–D-galactopyranoside per ml PBS containing 3 mM potas-
sium ferrocyanide and 1 mM magnesium chloride for 2 h at room
temperature. Blue cell clusters were counted and infection was ex-
pressed as foci forming units (ffu)/ml of cell culture supernatant.
2.6. Infectivity assay
The infective dose in cell culture supernatants (TCID50) was
monitored in PBMC as described [25]. In brief, donor PBMC from
a known HIV-1 seronegative subject were obtained from citrated
blood samples by a Ficoll-Paque gradient centrifugation. PBMC
were cultivated in RPMI 1640/15% FCS and prestimulated with
25 U IL-2/ml, 50 U of human MCSF (ICN-Biochemicals) and 5 lg/
ml PHA (Biochrome KG) for 3 days. Virus supernatants were di-
luted in 96-well plates according to the procedure described by
Reed and Muench [25], incubated with stimulated PBMC and cul-
tured for 9 days. On day 4 the 96-well plates were centrifuged (Sig-
ma GS6R, 1200 rpm, 2 min, RT) and 50% of the medium was
replaced against fresh medium. Infection was monitored by a stan-
dard p24 in-house assay on day 9 [23]. The speciﬁc infectivity was
expressed as the amount of infectious virus (TCID/ml) in a ﬂuid in
relation to the amount of virus present in this ﬂuid estimated by its
p24 antigen concentration (p24 ng/ml). To determine the speciﬁc
infectivity (TCID/ngp24), virus was propagated under identical con-
ditions and the growth of the laboratory strain NL4-3 was used as
an internal marker.
3. Results and discussion
3.1. Coreceptor usage of primary isolates and presence of N-glycan g15
Infection of PHA/IL-2 stimulated PBMC revealed that the pri-
mary isolates PI-932, PI-911 and PI-930 showed the syncytia
inducing (SI) phenotype. These viruses had a highly positively
charged V3 loop and showed a higher speciﬁc infectivity on PBMC
compared to the NSI primary isolates PI-903, PI-991, PI-951 (Table
1). An additional difference between NSI and SI viruses was the
presence of N-glycan g15 (Fig. 1A). Interestingly, all SI primary iso-
lates had mutations affecting the N-glycosylation site (NNT, aa
301–303) but also the N amino acid at position 300, leading to a
complete destruction of the highly conserved NNNT site
(NNNT > HNTV, SIQK, YRNA).
Infection of GHOST indicator cells revealed that viruses PI-903,
PI-991, andPI-951wereR5-monotropic, PI-930wasX4-monotropic,
whereas PI-911 and PI-932 were able to use CCR5/GPR15 or CCR5/
Table 2
Coreceptor usage of primary isolates.
HIV-1 primary
isolates
Coreceptora
CCR3 CCR5 CCR8 CXCR4 CXCR6 CX3CR1 GPR15
PI-903 – 50 – – – – –
PI-991 – 5000 – – – – –
PI-951 – 2000 – – – – –
PI-932 130 120 10 100 50 40 150
PI-911 – 2000 – 1500 – – 50
PI-930 – – – 30 – – –
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(Table 2). These data suggest that primary isolates usingCXCR4have
a signiﬁcantly higher speciﬁc infectivity compared to the R5-mono-
tropic viruses on PBMC,which is probably linked to altered corecep-
tor usage.
3.2. Autologous and heterologous neutralization of primary isolates
Next, we have investigated the ability of human serum samples
to neutralize the primary isolates. From the analysis of virus strains
lacking g15 because of NNT>QNT mutations it was suggested that
the non-glycosylated (g15) X4-tropic primary isolates were sen-
sitive to neutralization in contrast to the glycosylated (+g15) iso-
lates [2,4].
Firstly, we showed that all six viruses were resistant to neutral-
ization by autologous serum from the same time point (Table 3).
These results are in agreement with earlier observations [22],
which demonstrated that the isolation of cell-free viruses from
HIV-1 positive serum samples is selective for viruses that escaped
from autologous neutralization.
Secondly, when heterologous HIV-1 antibody-positive serum
samples were tested for neutralization, a signiﬁcant difference in
neutralization between g15 and +g15 viruses was observed. All
heterologous sera neutralized the +g15 primary isolates by >90%.
Against the g15 primary isolates, neutralization was highly
inconsistent and varied between 93% (S2 against PI-911) and 11%
(S6 against PI-911). These experiments showed that in each heter-
ologous serum, a strong neutralizing activity was present directed
against different primary isolates. However, in heterologous serum
samples, the neutralizing activity against the g15 viruses was
generally lower and more inconsistent compared to the potent
neutralizing activity directed against +g15 R5 monotropic viruses
(Table 3).
Based on these experiments we conclude that primary viruses
can escape from neutralization despite the lack of N-glycan g15
and that primary viruses can be efﬁciently neutralized despite
the presence of g15. Therefore, we hypothesized that the
differences in speciﬁc infectivity might be relevant to escape fromTable 3
Neutralization of primary isolates.
HIV-1 primary isolates V3 loop position 300–303 Virus neutralization (%)a
Autologous serum
PI-903 NNNT 3
PI-991 HNNT 5
PI-951 NNNT 5
PI-932 HNTV 11
PI-911 SIQK 12
PI-930 YRNA 14
a Neutralization of primary isolates was tested in PHA/IL-2 stimulated PBMC using 10neutralization. Interestingly, we could demonstrate that both
groups, the +g15 and g15 primary viruses, showed a signiﬁcant
difference in their speciﬁc viral infectivity (TCID/ngp24). In the
CD4–gp120 complex, the V3 loop is directed towards the cell sur-
face which facilitates binding of the V3 loop to the coreceptors
[9,10]. It is therefore conceivable, that mutations within the V3
loop can improve coreceptor binding and therefore can enhance
the viral infectivity to overcome antibody neutralization. It is also
conceivable, that the higher infectivity is due to the introduction of
charged amino acids Arg (YRNA) and Lys (SIQK) or the introduction
of a His (HNTV) amino acid into the NNNT region leading to a more
positively charged V3 loop.
Obviously, amino acids NNNT of the V3 loop are quite impor-
tant for viral infectivity. In a study by Nolan et al. [26], a mutant
of the X4R5 dualtropic strain R3A lacking NNNT (D5–8) was unable
to infect cells via CCR5 and its ability to use CXCR4 was reduced by
about 50%. Deleting the NNNT amino acids eliminates the V3 Asn
residues that are binding to the external loop of the CCR5 corecep-
tor [9,10]. Therefore, it is not surprising that NNNT deleted viruses
or viruses with a mutated NNNT sequence constitute no perfect
match for CCR5. For CXCR4, the elimination of NNNT together with
the elimination of negatively charged amino acids (D5–8, 28–29)
lead to a dramatic enhancement for CXCR4-speciﬁc infection. Thus,
lack of g15 and lack of negatively charged amino acids, which obvi-
ously generates a more open structure and a more positively
charged V3 loop, is an advantage for a more efﬁcient CXCR4 usage.
Based on these data, it is suggestive that the introduction of posi-
tively charged amino acids into the V3 loop can compensate the
loss of carbohydrate shielding. This is in agreement with our study,
where the loss of carbohydrate shielding was also compensated by
the addition of positively charged amino acids. Other atypical
mutations introducing Lys, Arg or His amino acids into the NNNT
region can also be found in 1–2% of the B subtype env sequences
published by the HIV sequence database [11]. In the study by
Low et al. [27], NNNT was conserved in almost 100% of their R5
samples, whereas mutations in the NNNT sequence were seen in
X4 samples preferentially at late stage of infection. A decreasing
immune function (i.e. loss of neutralizing antibody [28,29]) seems
to be correlated with genotypic changes. In a situation where
virus-neutralizing immune functions are impaired, the shielding
of the V3 loop by the N-glycan g15 is no longer necessary and
the virus can be further selected for increased infectivity. To study
the role of the speciﬁc mutations, which can be found in the NNNT
region we have introduced these mutations into the background of
the NL4-3 strain, generating viruses which only differ in these four
amino acids.
3.3. Neutralization of NL4-3 mutants with a mutated NNNT sequence
To investigate the role of NNNT mutants for viral infectivity we
have constructed mutants of the laboratory strain NL4-3Heterologous sera
S1 S2 S3 S4 S5 S6 S7 Means ± S.D.
94 90 97 92 90 95 90 93 ± 3
91 94 90 95 95 94 92 93 ± 3
93 90 92 93 93 92 93 92 ± 1
25 12 21 41 48 13 23 26 ± 13
12 93 79 57 91 11 42 54 ± 33
19 21 30 44 16 18 24 25 ± 9
00 TCID50 and 5% HIV-1 antibody positive human serum.
Table 4
Speciﬁc infectivity of NL4-3 V3 loop mutants.
NL4-3 V3 loop
mutants
Presence of N-glycosylation
site g15
Speciﬁc infectivitya TCID/
ngp24
NL-SIQK  14200
NL-YRNA  13600
NL-HNTV  13400
NL-NNNT(NL4-3) + 11600
NL-NQNT  9000
NL-NNNI  8100
NL-NNNK  7300
a Tested in the presence of normal human serum 1:100 in GHOST-CXCR4 cells.
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lates and three control mutants (NNNI, NNNK, and NQNT) (Fig. 1B).
Since NL4-3 by itself and all the constructed mutants were CXCR4-
monotropic, cell growth and neutralization was studied in the
standard GHOST-CXCR4 indicator cell line. Here we have observed
that NL-mutants carrying the in vivo selected mutations showed
higher speciﬁc infectivity compared to the +g15 NL4-3 strain and
the g15 controls (Fig. 2A, Table 4).
In cell cultures containing a HIV-1 positive serum mix the
NL4-3 +g15 virus showed resistance to neutralization (70%) fol-
lowed by NL-SIQK, NL-YRNA and NL-HNTV (Fig. 2B). All other
viruses with a lower speciﬁc infectivity, which are also lacking
g15, were neutralized. We have shown for our set of molecularly
cloned NL4-3 mutants that g15 is blocking neutralizing antibodies
to the NL4-3 V3 present in the HIV-positive serum mixture. Inter-
estingly, the mutants containing the in vivo selected g15 se-
quences were also resistant to neutralization in contrast to theFig. 2. Growth properties and neutralization of NL4-3 V3 loop mutants differing in
amino acids 300–303 (NNNT). (A) NL-mutants were grown in GHOST-CXCR4 cells in
the presence of a mixture of normal human sera. (B) NL-mutants grown in GHOST-
CXCR4 cells in the presence of a HIV-1 positive serum mixture. The serum mixtures
were applied in 1:100 dilution and cells were infected by using an infectious dose
equivalent to 0.25 ng of p24 antigen per 96-well. Shown are the averages of
triplicate wells. The S.D. of the mean was <15%.g15 controls. The data suggest that the lack of N-glycan g15
alone is not the only major determinant for the selection of X4-
tropic virus as proposed by Pollakis et al. [30]. Apart from the
fact, that the unshielded, more open structure of the V3 loop is
a much better ligand for CXCR4, a high speciﬁc infectivity is also
needed to compensate the antibody blocking effect of the V3 loop
carbohydrates. Therefore, the development of X4-tropic viruses
might be partially achieved by loss of glycosylation and atypical
mutations within that region, both leading to an altered, more
efﬁcient CXCR4 usage.
Acknowledgements
Specimens used in this study were all collected at the Bernhard
Nocht Institute for Tropical Medicine in Hamburg, Germany and
kindly provided by H. Sudeck, M. Dietrich and H. Schmitz. GHOST
indicator cells were kindly provided by D. Littman organized by
the Centralized Facility for AIDS Reagents and the UK Medical
Research Council. We thank M.T. Dittmar (Center for Infectious
Disease, Queen Mary’s School, London) for his kind support for
providing coreceptor data of patient isolates and M. Niedrig
(Robert-Koch Institute, Berlin) for providing p24-speciﬁc
monoclonal antibodies.
References
[1] Leonard, C.K., Spellman, M.W., Riddle, L., Harris, R.J., Thomas, J.N. and Gregory,
T.J. (1990) Assignment of intrachain disulﬁde bonds and characterization of
potential glycosylation sites of the type 1 recombinant human
immunodeﬁciency virus envelope glycoprotein (gp120) expressed in Chinese
hamster ovary cells. J. Biol. Chem. 265, 10373–10382.
[2] Back, N.K., Smit, L., De Jong, J.J., Keulen, W., Schutten, M., Goudsmit, J. and
Tersmette, M. (1994) An N-glycan within the human immunodeﬁciency virus
type 1 gp120 V3 loop affects virus neutralization. Virology 199, 431–438.
[3] Schonning, K., Jansson, B., Olofsson, S. and Hansen, J.E. (1996) Rapid selection
for an N-linked oligosaccharide by monoclonal antibodies directed against the
V3 loop of human immunodeﬁciency virus type 1. J. Gen. Virol. 77, 753–758.
[4] Polzer, S., Dittmar, M.T., Schmitz, H. and Schreiber, M. (2002) The N-linked
glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects
coreceptor usage, cellular tropism, and neutralization. Virology 304, 70–80.
[5] Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez,
J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., Komarova, N.L., Nowak, M.A., Hahn,
B.H., Kwong, P.D. and Shaw, G.M. (2003) Antibody neutralization and escape
by HIV-1. Nature 422, 307–312.
[6] de Parseval, A., Bobardt, M.D., Chatterji, A., Chatterji, U., Elder, J.H., David, G.,
Zolla-Pazner, S., Farzan, M., Lee, T.H. and Gallay, P.A. (2005) A highly conserved
arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via
sulfated motifs. J. Biol. Chem. 280, 39493–39504.
[7] Dalgleish, A.G., Beverley, P.C., Clapham, P.R., Crawford, D.H., Greaves, M.F. and
Weiss, R.A. (1984) The CD4 (T4) antigen is an essential component of the
receptor for the AIDS retrovirus. Nature 312, 763–770.
[8] Singer, I.I., Scott, S., Kawka, D.W., Chin, J., Daugherty, B.L., De Martino, J.A., Di
Salvo, J., Gould, S.L., Lineberger, J.E., Malkowitz, L., Miller, M.D., Mitnaul, L.,
Siciliano, S.J., Staruch, M.J., Williams, H.R., Zweerink, H.J. and Springer, M.S.
(2001) CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli
of human macrophages and T cells. J. Virol. 75, 3779–3790.
[9] Huang, C.C., Lam, S.N., Acharya, P., Tang, M., Xiang, S.H., Hussan, S.S., Stanﬁeld,
R.L., Robinson, J., Sodroski, J., Wilson, I.A., Wyatt, R., Bewley, C.A. and Kwong,
P.D. (2007) Structures of the CCR5 N terminus and of a tyrosine-sulfated
antibody with HIV-1 gp120 and CD4. Science 317, 1930–1934.
1206 S. Polzer et al. / FEBS Letters 583 (2009) 1201–1206[10] Huang, C.C., Tang, M., Zhang, M.Y., Majeed, S., Montabana, E., Stanﬁeld, R.L.,
Dimitrov, D.S., Korber, B., Sodroski, J., Wilson, I.A., Wyatt, R. and Kwong, P.D.
(2005) Structure of a V3-containing HIV-1 gp120 core. Science 310, 1025–
1028.
[11] Human Retroviruses and AIDS 1999: A Compilation and Analysis of Nucleic
Acid and Amino Acid Sequences. Part VII: Global Variation in the HIV-1 V3
Region (Kuiken, C.L., Foley B., Hahn, B., Marx, P.A., McCutchan, F., Mellors, J.W.,
Mullins, J.I., Wolinsky, S., and Korber, B., Eds.). Theoretical Biology and
Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
[12] Tian, H., Lan, C. and Chen, Y.H. (2002) Sequence variation and consensus
sequence of V3 loop on HIV-1 gp120. Immunol. Lett. 83, 231–233.
[13] Polzer, S., Dittmar, M.T., Schmitz, H., Meyer, B., Müller, H., Kräusslich, H.G. and
Schreiber, M. (2001) Loss of N-linked glycans in the V3-loop region of gp120 is
correlated to an enhanced infectivity of HIV-1. Glycobiology 11, 11–19.
[14] Losman, B., Biller, M., Olofsson, S., Schønning, K., Lund, O.S., Svennerholm, B.,
Hansen, J.E. and Bolmstedt, A. (1999) The N-linked glycan of the V3 region of
HIV-1 gp120 and CXCR4-dependent multiplication of a human
immunodeﬁciency virus type 1 lymphocyte-tropic variant. FEBS Lett. 454,
47–52.
[15] McCaffrey, R.A., Saunders, C., Hensel, M. and Stamatatos, L. (2004) N-linked
glycosylation of the V3 loop and the immunologically silent face of gp120
protects human immunodeﬁciency virus type 1 SF162 from neutralization by
anti-gp120 and anti-gp41 antibodies. J. Virol. 78, 3279–3295.
[16] Kwong, P.D., Doyle, M.L., Casper, D.J., Cicala, C., Leavitt, S.A., Majeed, S.,
Steenbeke, T.D., Venturi, M., Chaiken, I., Fung, M., Katinger, H., Parren, P.W.,
Robinson, J., Van Ryk, D., Wang, L., Burton, D.R., Freire, E., Wyatt, R., Sodroski, J.,
Hendrickson, W.A. and Arthos, J. (2002) HIV-1 evades antibody-mediated
neutralization through conformational masking of receptor-binding sites.
Nature 420, 678–682.
[17] Clevestig, P., Pramanik, L., Leitner, T. and Ehrnst, A. (2006) CCR5 use by human
immunodeﬁciency virus type 1 is associated closely with the gp120 V3 loop
N-linked glycosylation site. J. Gen. Virol. 87, 607–612.
[18] Malenbaum, S.E., Yang, D., Cavacini, L., Posner, M., Robinson, J. and Cheng-
Mayer, C. (2000) The N-terminal V3 loop glycan modulates the interaction of
clade A and B human immunodeﬁciency virus type 1 envelopes with CD4 and
chemokine receptors. J. Virol. 74, 11008–11016.
[19] Schønning, K. (2003) Antibody neutralization of human immunodeﬁciency
virus type 1 (HIV-1). APMIS Suppl. 111, 1–42.
[20] Wolk, T. and Schreiber, M. (2006) N-Glycans in the gp120 V1/V2 domain of the
HIV-1 strain NL4–3 are indispensable for viral infectivity and resistance
against antibody neutralization. Med. Microbiol. Immunol. 195, 165–172.[21] Johnson, W.E., Sanford, H., Schwall, L., Burton, D.R., Parren, P.W., Robinson, J.E.
and Desrosiers, R.C. (2003) Assorted mutations in the envelope gene of simian
immunodeﬁciency virus lead to loss of neutralization resistance against
antibodies representing a broad spectrum of speciﬁcities. J. Virol. 77, 9993–
10003.
[22] Schreiber, M., Petersen, H., Wachsmuth, C., Müller, H., Hufert, F.T. and Schmitz,
H. (1994) Antibodies of symptomatic human immunodeﬁciency virus type 1-
infected individuals are directed to the V3 domain of noninfectious and
not of infectious virions present in autologous serum. J. Virol. 68, 3908–
3916.
[23] Niedrig, M., Rabanus, J.P., L’Age Stehr, J., Gelderblom, H.R. and Pauli, G. (1988)
Monoclonal antibodies directed against human immunodeﬁciency virus (HIV)
gag proteins with speciﬁcity for conserved epitopes in HIV-1, HIV-2 and
simian immunodeﬁciency virus. J. Gen. Virol. 69, 2109–2114.
[24] Chesebro, B. and Wehrly, K. (1988) Development of a sensitive quantitative
focal assay for human immunodeﬁciency virus infectivity. J. Virol. 62, 3779–
3788.
[25] Johnson, V.A. and Byington, R.E. (1990) Quantitative assays for virus infectivity
in: Techniques of HIV Research (Aldovini, A. and Walker, B., Eds.), pp. 53–83,
Stockton Press, New York, NY.
[26] Nolan, K.M., Jordan, A.P. and Hoxie, J.A. (2008) Effects of partial deletions
within the human immunodeﬁciency virus type 1 V3 loop on coreceptor
tropism and sensitivity to entry inhibitors. J. Virol. 82, 664–673.
[27] Low, A.J., Marchant, D., Brumme, C.J., Brumme, Z.L., Dong, W., Sing, T., Hogg,
R.S., Montaner, J.S., Gill, V., Cheung, P.K. and Harrigan, P.R. (2008) CD4-
dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a
large population of therapy-naive individuals. AIDS Res. Hum. Retroviruses 24,
219–228.
[28] Schreiber, M., Wachsmuth, C., Müller, H., Hagen, C., Schmitz, H. and van
Lunzen, J. (1996) Loss of antibody reactivity directed against the V3 domain of
certain human immunodeﬁciency virus type 1 variants during disease
progression. J. Gen. Virol. 77, 2403–2414.
[29] Schreiber, M., Müller, H., Wachsmuth, C., Laue, T., Hufert, F.T., Van Laer, M.D.
and Schmitz, H. (1997) Escape of HIV-1 is associated with lack of V3 domain-
speciﬁc antibodies in vivo. Clin. Exp. Immunol. 107, 15–20.
[30] Pollakis, G., Kang, S., Kliphuis, A., Chalaby, M.I., Goudsmit, J. and Paxton, W.A.
(2001) N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein
as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol.
Chem. 276, 13433–13441.
